INTRODUCTION cle cells transduced to express G-CSF. Cells transduced with LrGSN, a retrovirus expressing rat G-CSF, were implanted ^^ ranltlocyte colony-stimulating factor (G-CSF) is a in the carotid artery and control animals received cells VJ cytokine that selectively stimulates the proliferation and transduced with LASN, a retrovirus encoding human differentiation of neutrophil precursors and accelerates neuadenosine deaminase. Test animals showed a doubling of trophil matoration and release from the martow (Demefri and neutrophil counts for at least 7 weeks, with mean values of Griffin, 1991; Morstyn and Dexter, 1993) . Recentiy, recombi-'Department of Pediatrics, University ofWashington, Seattle, WA 98195. ^Department of Biochemistry-IB, Unesp Rio Claro-SP, 13500, Brazil. nant G-CSF has been used to treat chronic neutropenias of various causes to decrease morbidity and mortality due to infection (Morstyn and Dexter, 1993) . Regardless of cause, treataient of neutropenic individuals with recombinant G-CSF often results in at least a partial normalization of neutrophil number and function. However, due to the symptomatic rather than curative natare of tiie treatment, these diseases often require lifelong daily injections with this honnone. In this category is cyclic hematopoiesis, a disease that occurs both in humans and grey collie dogs, and is characterized by cyclical variations in blood neutrophils, monocytes, lymphocytes, eosinophils, reticulocytes, and platelets due to periodic fluctoations in blood cell production by the bone martow (Dale et al, 1972; lones and Lange, 1983; Dale and Hammond, 1988) . The recurrent severe neutropenia leads to bacterial infections and shortened life expectancy. The disorder can be cured by bone marrow transplantation in grey collie dogs as well as in humans; and in both dogs and humans the disease can be transferted from an affected to a normal (Dale and Graw, 1974; Weiden et al, 1974; Krance et al, 1982) . This transplantability strongly supports the concept that this is a disease of defective regulation of hematopoietic stem cells. Although the underlying molecular defect is not known, long-term daily administration of recombinant G-CSF eliminates the severe recurtent neutropenia (Lothrop et al, 1988; Hammond etal, 1989 Hammond etal, ,1990 . The constimtive expression ofG-CSF by gene therapy would provide clinical and probably economic benefits.
The major colony-stimulating factors have been expressed in several cell types following gene transfer in vitro (Lang et al, 1985; Laker et al, 1987; Wong et al, 1987; Browder et al, 1989) , and the retrovims-mediated transfer and expression of interleukin-3 (IL-3) , granulocytemacrophage colony-stimulating factor (GM-CSF) , and G-CSF (Chang efaZ., 1989) in mouse hematopoietic cells in vivo has been described. The retrovirally expressed IL-3 and GM-CSF produced a fatal myeloproliferative syndrome in treated mice. Most noteworthy, however, long-term expression of G-CSF produced sustained neutrophilia that was not associated with disease (Chang et al, 1989) . Similarly, a mouse mammary tomor constitatively expressing G-CSF produced sustained neutrophilia in mice without myeloproliferative disease (Lee and Lottsfeldt, 1984) . The severe recurtent neutropenia in grey collie dogs was not abrogated by in vivo IL-3 or GM-CSF treatment (Hammond et al, 1990) . IL-3 caused eosinophilia, whereas recombinant human GM-CSF caused neutrophilia and eosinophilia, but with both agents cycling of hematopoiesis persisted (Hammond et al, 1990) . In contrast, G-CSF prevented the recurtent neutropenia and obliterated periodic fluctuation of monocyte, eosinophil, reticulocyte, and platelet counts (Lothrop et al, 1988; Hammond et al, 1990) .
We have shown in rats long-term expression of human ADA (Lynch et al, 1992; Clowes et al, 1994) and erythropoietin (Osbome et al, 1995) from transduced smooth muscle cells seeded into carotid arteries. In vascular injury, where the vessel is not completely re-endothelialized, vascular smooth muscle cells form a pseudoendothelium that is in direct contact with the blood (Clowes et al, 1983) . Vascular smooth muscle cells are readily obtained, cultured, transduced, and implanted, making these cells a generally useful target tissue for gene therapy. We recentiy cloned rat G-CSF (Han et al, 1996) and as a prelude to the treatment of collie dogs with cyclic hematopoiesis, we investigated the ability of transduced vascular smooth muscle cells to provide therapeutic levels of G-CSF in rats.
MATERIALS AND METHODS

Retroviral vectors
The G-CSF expression vector was made by digesting rat G-CSF cDNA (Han et al, 1996) with Eco RI and Dra I and ligating the isolated DNA fragment (700 bp) into the viral plasmid LXSN (Miller and Rosman 1989) , previously digested with Eco RI and Hpa I to provide tiie expression vector LrGSN. In LiGSN, rat G-CSF cDNA expression is driven by tiie strong viral LTR promoter and the neo resistance gene is expressed ffom SV-40 early region promoter/enhancer (Hock et al, 1989) . From PA317 packaging cell lines (Miller and Buttimore, 1986) , LiGSN had a viral titer of 8 X 10'^ cfu/ml. The retroviral vector LASN, which encodes nonsecreted human adenosine deaininase (ADA) (Hock et al, 1989) , was chosen as a control vector.
Cell culture and transduction
Ecotropic PE501 and amphotropic PA317 retrovims packaging cell lines (Miller and Buttimore, 1986; Miller and Rosman, 1989) , NIH-3T3 thymidine kinase-negative cells (MUler and Buttimore, 1986) , and primary cultures of rat vascular smooth muscle cells were grown in Dulbecco/Vogt-modified Eagle's medium (DMEM) with high glucose (4.5 gram/liter) supplemented with 10% fetal bovine seram in humidified 5% C02/95% air at 37°C.
Rat smooth muscle cell cultores were prepared by enzymatic digestion of the aorta from male Fisher 344 rats. These cells were characterized by positive staining for muscle cell-specific actins with HHF35 antibody (Geary et al, 1994 ) while staining negative for von Willebrand factor (Geary et al, 1994) , an endothelial cell-specific marker. Early-passage smooth muscle cells were exposed to 16-hr viras harvests from PA317-LrGSN and PA317-LASN amphotropic viras-producing cell lines for a period of 24 hr in the presence of Polybrene (4 figlml), and selected in G418 antibiotic (1 mg/ml).
G-CSF bioassay
Cytokine secretion ffom LrGSN-transduced cells was monitored using a murine cell line, NFS-60, that proliferates in response to G-CSF (Dale et al, 1992) . Recombinant canine G-CSF (kindly supplied by Amgen, Thousand Oaks, CA) was used to constract a proliferation-response curve with murine NFS-60 cells (Dale et al, 1992) . In brief, short-tenn proliferation was determined by measuring tritiated thymidine incorporation by cells seeded at a concentration of 10' cells/well in 96-well microtiter plates. Proliferative response to conditioned medium was measured after 24 hr at 37°C, 5% CO2 and harvesting the cells 4 hr later on fiberglass filters using an automated cell harvester (Cambridge Technology, Cambridge, MA).
Cell implantation
Male Fisher 344 rats (275-325 grams) were premedicated witti 0.04 mg/kg atropine subcutaneously and 2.5 mg/kg enrofloxacin i.m. and were anesthetized using 44 mg/kg ketamine, 5 mg/kg xylazine, and 0.5 mg/kg acepromazine i.p. Animals were placed in dorsal recumbency and an incision was made along the ventral midline of ttie neck from the angle of the mandible to the ttioracic inlet . The left common carotid and its intemal and extemal branches were exposed using blunt dissection. Temporary ligatures were placed around the caudal common carotid artery and the cranial extent of the intemal carotid. The extemal carotid was permanentiy ligated and an arterotomy made between this ligature and the bifiircation of the extemal and intemal branches. A Fogarty 2F arterial embolectomy cattieter was inserted through the arteriotomy site and the interior of the common carotid was balloon injured. The balloon cattieter was withdrawn and a 24-gauge angiocatheter (Becton Dickinson) was inserted. A total of 2 X 10* transduced vascular smooth muscle cells were introduced into the lumen of the common carotid artery and allowed to seed the artery wall for 15 min. The angiocatiieter was withdrawn and the arteriotomy site was closed by placing a second permanent ligatare around the external carotid artery just caudal to the site. Blood flow was re-established through the common carotid artery and the intemal carotid artery and the incision was closed.
Blood counts
Anticoagulated blood samples (100 fil) were obtained from the tail vein with the animals under light ether anesthesia. Samples were obtained from 19 days before surgery and from 3 to 7 days post surgery for up to 7 weeks. Total white blood cells (WBC) platelets, and hematocrit values were determined using a Coulter T-540 counter and differential WBC counts were obtained manually. muscle cells, using PA 317-LASN packaging cells and LASNtransduced smooth muscle cells, respectively, to provide control medium. G-CSF expression was 2 ng/24 hr per iC cells from packaging cells and 8 ng/24 hr per IO'' cells from transduced smooth muscle cells. These assays indicate expression of a bioactive gene product from our retroviral vector, but are probably an underestimate because purified rat G-CSF was not available and recombinant canine G-CSF was used to generate a standard curve.
The absolute neutrophil counts of animals receiving LrGSNtransduced cells increased rapidly after cell implantation, and by day 10 a relatively constant elevated plateau had been achieved which was sustained for at least 7 weeks (Fig. 1) . In contrast, neutrophti counts obtained before and after surgery from animals seeded with LASN-transduced cells did not show changes (Fig. 1) . This suggests that the consequences of surgery were not responsible for the increased number of neutrophils observed in the test rats. The surgical procedure was well tolerated by the animals, witii no evidence of fever or other malaise, and this may be reflected in the lack of neutrophil increases in animals receiving LASN-transduced cells. Pooled hematopoietic cell data from 6 control and 8 test rats are shown in Table 1 . Neutrophil counts recorded from rats after LrGSNcell implantation were significantiy elevated over control rats receiving LASN-transduced cells (p < 0.001). A simtiar statistical comparison of platelets, lymphocytes, and red cells, as measured by hematocrit, showed no significant differences (p > 0.05). This is noteworthy as previous stadies of G-CSF administration to mice have shown reduction in red cell numbers Pojda et al, 1990) .
DISCUSSION
We have shown that retrovirally transduced vascular smooth muscle cells allow sustained expression of G-CSF that stimulated significantiy elevated neutrophil production for periods of up to 7 weeks. In treated rats, we documented mean increases of 1,800 neutrophils//Al, which would be a therapeutic cell number for patients with severe chronic neutropenia or cyclic hematopoiesis. In these patients and cyclic neutropenic dogs, provision of neutrophil counts in excess of 5001 fll prevent severe recurtent infection and would be therapeutic (Lothrop et al, 1988; Hammond et al, 1989; Morstyn and Dexter, 1993) .
We observed no significant differences in lymphocyte and platelet numbers and hematocrit between animals treated with G-CSF-expressing cells and controls, indicating vector-encoded G-CSF production stimulated neutrophil production without other hematological effects. This is of interest because previous stodies in mice have shown that G-CSF administration caused reduced erythropoiesis and anemia Pojda et al, 1990) . Because long-term administi-ation of recombinant G-CSF to humans (Morstyn et al, 1988; Morstyn and Dexter, 1993) and dogs (Hammond et al 1989 (Hammond et al , 1990 specifically stimulates neutrophil production, our data suggest that rats provide a more appropriate human model for the physiological study of G-CSF administration than mice. G-CSF expression, unlike GM-CSF and n..-3 , did not cause pathological changes in hematopoiesis. In previous studies, these latter cytokines produced a fatal myeloproliferative syndrome in mice Wong et al, 1989) .
The implantation of genetically modified vascular smootii muscle cells to patients will requke an approach ottier than arterial seeding. Recentiy, we proposed tiie seeding of synthetic PTFE (polytetrafluoroethylene) grafts as a method to retum transduced vascular smooth muscle cells to their donor (Geary et al, 1994) and this technique can be readily stodied in collie dogs with cyclic hematopoiesis, an appropriate clinical model for affected patients (Dale et al, 1988; Lothrop et al, 1988) . We have shown that the rat carotid artery seeding procedure resulted in approximately 10' cells being retained within the artery (Osbome et al, 1995) . On the basis of this fmding, we estimate that the potentially therapeutic level of neutrophils we observed in rats was derived from 10' transduced cells. We previously estimated that 10* transduced cells can be seeded into a 10-cm X 4-mm PTFE graft (Osbome et al, 1993; Geary et al, 1994) and from the curtent study, this should provide a therapeutic level of G-CSF to a dog. It is also probable that neutropenic dogs and patients are more sensitive to G-CSF than normals.
Our data show that transduced vascular smooth muscle cells do not inactivate retroviral vector sequences, in agreement with previous studies of retrovirally mediated gene expression in these target cells (Lynch et al, 1992; Clowes et al, 1994; Osbome et al, 1995) . This is in contrast to skin fibroblasts where vector inactivation has been documented in both rats (Palmer et al, 1991) and dogs (Ramesh et al, 1993) . Thus, data is accumulating to show that vascular smooth muscle cells provide an ideal target tissue for gene therapy. These cells are readily obtained, cultored, transduced, and retumed to their donor. Implantation of these cells in the blood circulation suggests that their use for the secretion of not only hormones but also clot- ting factors for the treatment of patients with hemophilia and enzymes for treatment of lysosomal storage disorders.
